Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months
June 6, 2022
- reSET® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of substance use disorder (SUD), including alcohol, cannabis, cocaine, and stimulants
- Results support the real-world value of reSET, demonstrating durable treatment outcomes and reductions in healthcare resource utilization
6-month analysis is the first ever describing real-world health economic outcomes in patients undergoing treatment for multiple substance use disorders, and
whowere treated with reSET, demonstrating a 50% reduction in hospital encounters and > $3,500per patient cost savings1
Results from a real-world study of reSET showed a statistically significant reduction in overall hospital encounters and an estimated
This health economic study was accepted for publication and made available via pre-print by the international peer-reviewed journal Advances in Therapy.1
“Pear now has a continuum of evidence supporting our three FDA-authorized prescription digital therapeutics, including randomized controlled trials, real-world clinical data, and real-world health economic data,” said
The study evaluated real-world insurance claims from 101 adult patients with SUD treated with reSET, in the 6 months after initiation of reSET, and compared them to the claims six months prior to treatment and found:
- Overall hospital encounters were reduced by 50% (IRR: 0.50; 95% CI: 0.37-0.67; P<0.001), a statistically significant decrease. Hospital encounters included reductions in:
- Inpatient stays (56% reduction; IRR: 0.44; 95% CI: 0.26-0.76; P=0.003).
- Partial hospitalizations (57% reduction; IRR: 0.43; 95% CI: 0.21-0.88; P=0.021).
- Emergency department visits (45% reduction; IRR: 0.55; 95% CI: 0.38-0.80; P<0.004).
$3,591reduction in per-patient costs.1
The full paper is available online by clicking here.
reSET and its clinical intervention have been evaluated in randomized controlled trials, in real-world use and clinical outcomes, and now health economic outcomes.1-5
reSET Important Safety Information
Indications for Use:
reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older,
It is intended to:
- increase abstinence from a patient’s substances of abuse during treatment, and
- increase retention in the outpatient treatment program.
Important Safety Information for Clinicians:
Warnings: reSET is intended for patients whose primary language is English with a reading level of 7th grade or above, and
Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.
reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.
Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.
The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.
The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.
This Press Release does not include all the information needed to use reSET safely and effectively. Please see the Clinician Brief Summary for reSET for more information.
Neel Shah, Fulton F. Velez, Sam Colman, Laura Kauffman, Charles Ruetsch, Kathryn Anastassopoulos& Yuri Maricich(2022). Real-world reductions in healthcare resource utilization over 6 months in patients with substance use disorders treated with a prescription digital therapeutic. Advances in Therapy. 2022; https://doi.org/10.6084/m9.figshare.19950266.v3.
Campbell ANC, Nunes EV,
Matthews AG, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683-690.
Chaple M, Sacks S, McKendrick K, et al. (2016): A Comparative Study of the Therapeutic Education System for Incarcerated Substance-Abusing Offenders.
The Prison Journal. 96(3):485-508. doi:10.1177/0032885516636858
Xiong X, Braun S, Shafai G, Hare B, Luderer H, Stitzer M, Maricich Y. A Prescription Digital Therapeutic for Substance Use Disorder: Real World Engagement and Abstinence Patterns. Poster presented at: AcademyHealth;
June 4-7, 2022; Washington, DC.
Luderer H, Campbell A, Nunes E, Enman N, Xiong X, Gerwein R, Maricich Y. Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes.
Journal of Substance Use Disorders. 132 (2021) 108585. https://doi.org/10.1016/j.jsat.2021.108585
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005657/en/
Media and Investors:
Senior Director, Corporate Communications